Harb, WA, Diefenbach, CS, Lakhani N, Rutherford SC, Schreeder MT, Ansell SM, Sher T, Aboulafia DM, Cohen JB, Nix D, Landrette S, Flanders K, Miller LL, Lichenstein H, Abramson JS. Phase 1 Clinical Safety, Pharmacokinetics (PK), and Activity of Apilimod Dimesylate (LAM-002A), a First-in-Class Inhibitor of Phosphatidylinositol-3-Phosphate 5-Kinase (PIKfyve), in Patients with Relapsed or Refractory B-Cell Malignancies. https://doi.org/10.1182/blood.V130.Suppl_1.4119.4119 Blood
Recommends
Please login to recommend the paper.
Comments
No Available Comments
Make a Comment
To make a comment you must login or register.